Key Highlights
- Cigna slid for a second day as managed care stocks fell.
- Its decline was milder than those of the hardest-hit insurers.
- CMS proposed broader Medicare Advantage audits in a rule released Monday.
- Political focus on pharmacy benefit managers would matter for Evernorth.
Sold with the group
The Cigna Group (NYSE:CI) slid during Wednesday's session as managed-care stocks fell for a second straight day. The pressure came from a proposed rule by the Centers for Medicare & Medicaid Services, released Monday, that would broaden audits of Medicare Advantage plans and expand how much the government could recover.
Cigna's decline was milder than those of the hardest-hit names. Humana (NYSE:HUM) finished as the worst performer in the S&P 500, UnitedHealth Group (NYSE:UNH) was the biggest drag on the Dow Jones Industrial Average, and Elevance Health (NYSE:ELV), Centene (NYSE:CNC), CVS Health (NYSE:CVS) and Molina Healthcare (NYSE:MOH) all fell sharply. Health care was the second-worst S&P 500 sector, behind only energy.
The Dow closed down 561.25 points at 50,198.17, with health care pushing it to its session low. The S&P 500 slipped 16.90 points to 7,323.63, its fifth straight loss and its longest losing streak since June.
A different Business mix
Cigna's profile helps put its move in context. The company sold its Medicare Advantage business to Health Care Service Corp. In 2025, leaving it focused on employer-sponsored health coverage and on Evernorth, its health services unit, which includes the Express Scripts pharmacy benefit manager and specialty pharmacy operations.
That means the CRUSH proposal bears less directly on Cigna's current operations than on Medicare-focused insurers. Still, when a sector sells off on regulatory news, stocks with less direct exposure often fall alongside peers as investors reduce holdings across the group.
Cigna has also drawn political attention. Sen. Elizabeth Warren wrote on X that UnitedHealth, CVS and Cigna "each own a health insurer, pharmacy middleman, and pharmacy" and "take a cut at every step."
What CMS is proposing
The rule is called Comprehensive Regulations to Uncover Suspicious Healthcare, or CRUSH. It would let CMS extrapolate findings from risk adjustment data validation audits, or RADV audits, from a sample of medical records to an entire Medicare Advantage contract, starting with payment year 2018. CMS estimates the rule could save about $90 billion over 10 years.
CMS Administrator Dr. Mehmet Oz framed the proposal as a way to "crush fraud, waste, and abuse." The rule sets audit methods for the program as a whole and does not single out any company. It is not final, and comments are due January 19, 2027.
One analyst said that "The substantially larger collection estimate reflects broader auditing," and that CMS "could choose to make adjustments in the final rule." Oppenheimer expects legal challenges. The proposal revives a 2023 RADV rule that a Texas federal judge vacated in September 2025 in a case brought by Humana.
The rate backdrop
Broader markets offered little support. Minutes from the Federal Reserve's October meeting showed "almost all participants judged that, under their baseline outlooks for Inflation and the labor market," further increases in the federal funds rate "would likely be appropriate."
Why Evernorth Matters More Than Medicare Advantage for Cigna
The comment period through January 19, 2027, will be the main venue for the industry's response, and CMS could revise the rule before finalizing it. Investors will watch whether selling in less-exposed names such as Cigna fades once the details are digested.
UnitedHealth's 2027 outlook, due before year-end, could offer a sector-wide read. Any further political focus on pharmacy benefit managers would also be relevant for Cigna's Evernorth unit.

_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)



Please wait processing your request...